A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).

A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
复制标题

PDGFRB 与 TSC1(mTOR 信号通路内在抑制因子)在患有 t(5;9)(q32;q34) 的慢性嗜酸性粒细胞白血病患者中的新型融合

DOI:
10.1080/10428194.2018.1427855
复制
发表时间:
2018-10
影响因子:
2.6
通讯作者:
--
中科院分区:
医学4区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

PDGFRB 基因是与嗜酸性粒细胞增多相关的骨髓/淋巴肿瘤中染色体易位的常见靶标[1]。 PDGFRB 涉及的典型异常核型是 5q31-33 的标志性重排。迄今为止,已发现30多种不同的PDGFRB融合体[2]。酪氨酸激酶抑制剂伊马替尼被认为是治疗伴有嗜酸性粒细胞增多的 PDGFRB 重排肿瘤的最终治疗方法,据报道,伊马替尼 400 mg/d 或伊马替尼 100 mg/d 足以诱导完全缓解[3]。在这里,我们报告了在嗜酸性粒细胞增多症 MPN 患者中检测到一种新型 PDGFRB 融合体 TSC1-PDGFRB。此外,我们将TSC1-PDGFRB和muTSC1-PDGFRB T681I cDNA构建到MSCV-IRES-GFP中,并转导Ba/F3细胞。然后,在 TSC1-PDGFRB 或 muTSC1- 转导的 Ba/F3 细胞中研究 TKI(伊马替尼、尼罗替尼)和 mTOR 抑制剂(torin、雷帕霉素)的效率。
The PDGFRB gene is a frequent target of chromosomal translocation in myeloid/lymphoid neoplasms associated with eosinophilia [1]. The typical abnormal karyotype involved in PDGFRB is a hallmark rearrangement of 5q31-33. So far, more than 30 different PDGFRB fusions have been discovered [2]. The tyrosine kinase inhibitor imatinib is considered definitive treatment for PDGFRB-rearranged neoplasms with eosinophilia, and it has been reported that either imatinib 400 mg/d or imatinib 100 mg/d is sufficient to induce complete remission [3]. Here, we reported the detection of a novel PDGFRB fusion, TSC1-PDGFRB in a patient with eosinophilia, MPN. In addition, we constructed TSC1-PDGFRB and muTSC1-PDGFRB T681I cDNA into MSCV-IRES-GFP, and transduced Ba/F3 cells. Then, the efficiency of TKIs (imatinib, nilotinib) and mTOR inhibitors (torin, rapamycin) were investigated in those Ba/F3 cells transduced by TSC1-PDGFRB or muTSC1-
DOI: 10.1007/s00277-017-3067-x
发表时间: 2017-09-01
影响因子: 3.5
作者:
Jawhar, Mohamad;Naumann, Nicole;Metzgeroth, Georgia
通讯作者: Metzgeroth, Georgia
DOI: 10.1371/journal.pbio.1000038
发表时间: 2009-02-10
期刊: PLoS biology
影响因子: 9.8
作者:
Feldman ME;Apsel B;Uotila A;Loewith R;Knight ZA;Ruggero D;Shokat KM
通讯作者: Shokat KM
DOI: 10.5483/bmbrep.2016.49.1.201
发表时间: 2016-01
期刊: BMB reports
影响因子: 3.8
作者:
Park S;Sim H;Lee K
通讯作者: Lee K
DOI: 10.1126/science.277.5327.805
发表时间: 1997-08-08
期刊: SCIENCE
影响因子: 56.9
作者:
vanSlegtenhorst, M;deHoogt, R;Kwiatkowski, DJ
通讯作者: Kwiatkowski, DJ
DOI: 10.1038/sj.onc.1209990
发表时间: 2007-03-22
期刊: ONCOGENE
影响因子: 8
作者:
Wan, X.;Harkavy, B.;Helman, L. J.
通讯作者: Helman, L. J.